Appointment dossier — Uterine Serous Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Uterine Serous Carcinoma
- Trastuzumab Deruxtecan — Human evidence · 2 positive · PMID 39639215, 37676984
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
- Cisplatin — Human evidence · 0 positive / 2 negative-mixed · PMID 35106124, 1526508
- Cyclophosphamide — Human evidence · 0 positive / 1 negative-mixed · PMID 1526508
- Doxorubicin — Human evidence · 0 positive / 1 negative-mixed · PMID 1526508
- Lenvatinib — Review evidence · 2 positive · PMID 36447064, 34210768, 36874745
- Paclitaxel — Lab evidence · 2 positive · PMID 30174791, 24328598
- Pembrolizumab — Review evidence · 2 positive · PMID 36447064, 34210768, 36874745
- Carboplatin — Review evidence · 1 positive · PMID 24328598
- Olaparib — Animal evidence · 1 positive · PMID 41814851
- Sulfasalazine †Rx — Lab evidence · 0 positive / 1 negative-mixed · PMID 35106124
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT02491099 · Phase 2 — A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (United States)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT05231122 · Phase 2 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer (United States)
- NCT06369155 · Phase 2 — Azenosertib in Uterine Serous Carcinoma: Biomarker Study (United States)
- NCT06792552 · Phase 1 — A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors (United States)
- NCT06476808 · Phase 1 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. (United States)
- NCT05049538 — Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers (United States)
- NCT06526819 · Phase 1 / Phase 2 — SMP-3124LP in Adults With Advanced Solid Tumors (United States)
- NCT05579366 · Phase 1 / Phase 2 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (United States)
- NCT05150691 · Phase 1 / Phase 2 — A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (United States)
- NCT04969315 · Phase 1 / Phase 2 — TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors (United States)
- NCT06128551 · Phase 1 / Phase 2 — Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (United States)
- NCT07186842 · Phase 1 / Phase 2 — A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (United States)
- NCT06330064 · Phase 1 / Phase 2 — A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (United States)
- NCT04389632 · Phase 1 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors (United States)
- NCT05039801 · Phase 1 — IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (United States)
Most-relevant first: trials that name Uterine Serous Carcinoma, then broader trials you may still qualify for. 23 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Sulfasalazine †Rx × sulfa_allergy_drugs (high-stakes) — Contraindicate (high)
- Sulfasalazine †Rx × folate_antagonists — Monitor (moderate)
- Sulfasalazine †Rx × Cisplatin — Synergize (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Trastuzumab Deruxtecan has been studied in people for Uterine Serous Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Trastuzumab-Deruxtecan (T-Dxd) has been studied in people for Uterine Serous Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Cisplatin has been studied in people for Uterine Serous Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05256225), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?